New antibody therapy targets blood cancers in early trial
NCT ID NCT05424822
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new drug called JNJ-80948543 in people with non-Hodgkin lymphoma or chronic lymphocytic leukemia whose cancer has returned or not responded to other treatments. The drug works by redirecting the body's T-cells to attack cancer cells. The main goals are to check safety and find the best dose. About 167 participants will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aichi Cancer Center
Nagoya, 464 8681, Japan
-
Aidport Sp z o o
Skorzewo, 60-185, Poland
-
CHRU de Lille Hopital Claude Huriez
Lille, 59037, France
-
Carmel Medical Center
Haifa, 34362, Israel
-
Chongqing University Cancer Hospital
Chongqing, 400044, China
-
City of Hope
Duarte, California, 91010, United States
-
Hadassah Medical Center
Jerusalem, 9112001, Israel
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Institut Curie
Paris, 75005, France
-
Institut Universitaire du cancer de Toulouse-Oncopole
Toulouse, 31059, France
-
Institut de Cancerologie Strasbourg Europe ICANS
Strasbourg, 67033, France
-
Linear Clinical Research Ltd
Nedlands, 6009, Australia
-
Macquarie University Hospital
Macquarie University, 2109, Australia
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
National Cancer Center Hospital East
Kashiwa, 277 8577, Japan
-
Odense University Hospital
Odense, 5000, Denmark
-
Rigshospitalet
Copenhagen, 2100, Denmark
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Scientia Clinical Research
Randwick, 2031, Australia
-
Seattle Cancer Care Alliance
Seattle, Washington, 98109, United States
-
Sun Yat Sen University Cancer Center
Guangzhou, 510060, China
-
Tel Aviv Sourasky Medical Center
Tel Aviv, 64239, Israel
-
Texas Transplant Institute
San Antonio, Texas, 78229, United States
-
The Alfred Hospital
Melbourne, 3004, Australia
-
The Cancer Institute Hospital of JFCR
Tokyo, 135 8550, Japan
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Tianjin cancer hospital
Tianjin, 300060, China
-
Union Hospital Tongji Medical College of Huazhong University of Science and Technology
Wuhan, 430030, China
-
Uniwersyteckie Centrum Kliniczne Osrodek Badan Klinicznych Wczesnych Faz
Gdansk, 80 214, Poland